
MLYS Stock Forecast & Price Target
MLYS Analyst Ratings
Bulls say
Mineralys Therapeutics has established a compelling case for its product candidate, lorundrostat, which has shown a significant placebo-adjusted blood pressure reduction exceeding 10mmHg, garnering positive attention from prescribers. The product's robust profile in treating uncontrolled and resistant hypertension positions it favorably against competitors, particularly in the context of the positive data from the Advance-HTN trial. Anticipated feedback from the FDA and an upcoming New Drug Application (NDA) submission further strengthen the outlook for lorundrostat and the company’s potential market presence.
Bears say
Mineralys Therapeutics Inc faces significant risks that contribute to a negative outlook on its stock, particularly related to its developmental candidate, lorundrostat. Key concerns include the potential failure to meet peak commercial revenue estimates due to challenges in market size and penetration rates, alongside pricing issues. Furthermore, there are substantial uncertainties regarding the company's ability to secure necessary capital for ongoing operations and the future of its program development and commercialization efforts.
This aggregate rating is based on analysts' research of Mineralys Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MLYS Analyst Forecast & Price Prediction
Start investing in MLYS
Order type
Buy in
Order amount
Est. shares
0 shares